<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>南非令人恐惧的22％疫苗功效伴随着警告 Scary 22% vaccine efficacy in South Africa comes with heaps of caveats</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Scary 22% vaccine efficacy in South Africa comes with heaps of caveats<br/>南非令人恐惧的22％疫苗功效伴随着警告 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-02-09 21:12:28</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/2/4456753d139ecb111492fd59877b7e3f.jpg"><img src="http://img2.diglog.com/img/2021/2/4456753d139ecb111492fd59877b7e3f.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Dismal preliminary data on AstraZeneca’s COVID-19 vaccine in South Africa—where the B.1.351/ 501Y.V2 coronavirus variant is spreading widely—lead the government there to rethink its vaccination rollout and raised further international  concern about the variant.</p><p>关于AstraZeneca的COVID-19疫苗在南非（B.1.351 / 501Y.V2冠状病毒变种正在广泛传播）的惨淡初步数据，导致那里的政府重新考虑了其疫苗接种工作，并引起了国际对该变种的进一步关注。</p><p> But the small study has so many limitations and caveats, experts caution that drawing any conclusions from it is difficult.</p><p> 但是，这项小型研究存在许多局限性和警告，专家警告说，很难从中得出任何结论。</p><p> The study, which has not been published or peer-reviewed but presented in  a press conference Sunday, began in June and enrolled only around 2,000 participants, about half of which received a placebo. Early in the study—before B.1.351 emerged—the vaccine appeared over 70 percent effective at preventing mild-to-moderate cases of COVID-19. That is largely in line with the conclusion of an international Phase III trial released by AstraZeneca and vaccine co-developer Oxford University, which showed  mixed results for the replication-deficient adenovirus-based vaccine but an overall efficacy of  around 70 percent.</p><p> 该研究尚未发表或经过同行评审，但在周日的新闻发布会上进行了介绍，该研究于6月开始，仅招募了2,000名参与者，其中约一半接受了安慰剂治疗。在研究的早期（B.1.351出现之前），该疫苗对预防轻度至中度COVID-19病例的有效性似乎超过70％。这在很大程度上与阿斯利康和疫苗共同开发者牛津大学发布的国际III期临床试验的结论一致，该试验显示基于复制缺陷型腺病毒的疫苗的结果参差不齐，但总体功效约为70％。</p><p> But toward the end of the year—when cases of B.1.351 began taking off—the South African results shifted dramatically. The overall efficacy of the vaccine dropped to just 22 percent against mild-to-moderate COVID-19. In an analysis comparing efficacy solely in cases known to be due to B.1.351, the vaccine fared even worse, showing an abysmal efficacy of just 10 percent.</p><p> 但是到了年底，当B.1.351病例开始起飞时，南非的结果发生了巨大变化。该疫苗针对轻度至中度COVID-19的总体功效仅下降至22％。仅在已知由于B.1.351引起的病例中比较功效的分析中，该疫苗的表现甚至更差，显示出仅10％的糟糕的功效。</p><p> On first glance, those numbers are startling, and they suggest that the B.1.351 variant rendered the otherwise effective vaccine nearly useless. But, with a closer look, those numbers are almost uninterpretable. The trial was just too small to produce statistically solid results. Thus, each efficacy calculation has huge confidence intervals. For instance, the vaccine’s ending efficacy of 22 percent—based on a total of 42 coronavirus infections in the trial—had a plausible estimate range of between -50 percent effective and 60 percent effective.</p><p> 乍一看，这些数字令人吃惊，它们表明B.1.351变体使原本有效的疫苗几乎毫无用处。但是，仔细观察，这些数字几乎无法解释。该试验太小，无法产生统计上可靠的结果。因此，每个功效计算都具有巨大的置​​信区间。例如，基于该试验中总共42次冠状病毒感染，该疫苗的最终效力为22％，其有效范围估计在-50％至60％之间。</p><p>     The study also was not designed to answer the critical question of whether the vaccine can prevent severe disease, hospitalization, and death. The people enrolled in the trial were relatively young—median age of 31—with very low rates of underlying conditions. Both of those factors make people far less likely to develop severe COVID-19 and die from the disease.</p><p>     该研究还没有旨在回答疫苗是否可以预防严重疾病，住院和死亡的关键问题。参加该试验的人群相对较年轻（中位年龄为31岁），潜在疾病发生率很低。这两个因素使人们患严重COVID-19和死于疾病的可能性大大降低。</p><p> Experts emphasize that preventing severe disease and death is the most crucial goal of vaccines—not preventing transmission or mild illnesses. Last month, Johnson &amp; Johnson announced that its vaccine—which is an adenovirus-based vaccine, like AstraZeneca’s—was  only 57 percent effective against moderate and severe COVID-19 in South Africa. But, experts applauded the finding that it was 85 percent effective at preventing severe disease and death. And the company reported that no one vaccinated in its Phase III trial ended up being hospitalized or dying from the disease. Many experts championed the  not-yet-authorized vaccine as a potential new tool for ending the pandemic.</p><p> 专家强调，预防严重疾病和死亡是疫苗的最关键目标，而不是预防传播或轻度疾病。上个月，强生约翰逊宣布，其疫苗（这是一种基于腺病毒的疫苗，就像阿斯利康的一样）在南非针对中度和重度COVID-19的有效率仅为57％。但是，专家们称赞这一发现对预防严重疾病和死亡具有85％的效果。该公司报告说，在其第三阶段试验中没有接种疫苗的人最终没有住院或死于该疾病。许多专家拥护尚未批准的疫苗，作为终止大流行的潜在新工具。 </p><p>  The critical looming question is now whether AstraZeneca’s vaccine will likewise protect against severe disease and death in cases involving B.1.351, which has now been detected in more than 30 countries. Given the uncertainty, researchers and officials in South Africa said on Sunday that they would, for now, pause the rollout of AstraZeneca’s vaccine, which was  authorized for use in the European Union on January 29. (It has not yet been submitted to the US Food and Drug Administration for authorization.) South Africa had recently begun offering it to healthcare workers. Instead, officials there are now looking into the possibility of a phased rollout, which might involve vaccinating just 100,000 people and monitoring them over some time to look at hospitalization rates. If the vaccine looks effective at that point, they would then roll the vaccine out further. “Put very simply, we don’t want to end up with a situation where we vaccinated a million people or two million people with a vaccine that may not be effective in preventing hospitalization and severe disease,” Salim Abdool Karim, the co-chair of South Africa’s Ministerial Advisory Committee on COVID-19, said in  a press conference Monday.</p><p>现在迫在眉睫的关键问题是，在涉及B.1.351的病例中，阿斯利康的疫苗是否同样能防止严重疾病和死亡，目前已在30多个国家中发现。鉴于不确定性，南非的研究人员和官员周日表示，他们将暂时暂停阿斯利康疫苗的推出，该疫苗已于1月29日在欧盟获准使用。（尚未提交给美国。美国食品药品监督管理局（FDA）批准。）南非最近开始向医护人员提供该药品。取而代之的是，那里的官员现在正在研究分阶段实施的可能性，这可能涉及仅给100,000人接种疫苗，并在一段时间内对其进行监视，以查看住院率。如果疫苗在那时看起来有效，那么他们将进一步推出疫苗。 “很简单，我们不想结束这样的情况：我们给一百万或两百万人接种了可能无法有效预防住院和严重疾病的疫苗，”联合主席Salim Abdool Karim南非关于COVID-19的部长级咨询委员会的发言人周一在新闻发布会上说。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2021/02/scary-22-vaccine-efficacy-in-south-africa-comes-with-heaps-of-caveats/">https://arstechnica.com/science/2021/02/scary-22-vaccine-efficacy-in-south-africa-comes-with-heaps-of-caveats/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/功效/">#功效</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/efficacy/">#efficacy</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>